Rebekka Duhen

2.4k total citations · 1 hit paper
21 papers, 1.4k citations indexed

About

Rebekka Duhen is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Rebekka Duhen has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 13 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Rebekka Duhen's work include Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and T-cell and B-cell Immunology (6 papers). Rebekka Duhen is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and T-cell and B-cell Immunology (6 papers). Rebekka Duhen collaborates with scholars based in United States, Netherlands and Türkiye. Rebekka Duhen's co-authors include Thomas Duhen, Daniel Campbell, Antonio Lanzavecchia, Federica Sallusto, Tiffany C. Blair, Estelle Bettelli, Simon Glatigny, Mohamed Oukka, Andrew D. Weinberg and Rom S. Leidner and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rebekka Duhen

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

2018 564 citations Thomas Duhen, Rebekka Duhen et al. Nature Communications profile →

Peers

Countries citing papers authored by Rebekka Duhen

Since Specialization

Citations

This map shows the geographic impact of Rebekka Duhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebekka Duhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebekka Duhen more than expected).

Fields of papers citing papers by Rebekka Duhen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebekka Duhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebekka Duhen. The network helps show where Rebekka Duhen may publish in the future.

Co-authorship network of co-authors of Rebekka Duhen

This figure shows the co-authorship network connecting the top 25 collaborators of Rebekka Duhen. A scholar is included among the top collaborators of Rebekka Duhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebekka Duhen. Rebekka Duhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Engineering and biofabrication of early cancer models 2025 ·Nature Reviews Bioengineering ·(unknown), Alexander E. Davies, Carolyn E. Schutt, Ellen M. Langer, Rebekka Duhen, Prima Dewi Sinawang, Demir Akin, Utkan Demirci, Sadik C. Esener, Rebecca C. Fitzgerald, Luiz E. Bertassoni	0
2	Host-microbe-cancer interactions on-a-chip 2025 ·Frontiers in Bioengineering and Biotechnology ·(unknown), (unknown), (unknown), (unknown), Rebekka Duhen, Zhenzhen Zhang, Cristiane Miranda França, Luiz E. Bertassoni	1
3	Host-derived growth factors drive ERK phosphorylation and MCL1 expression to promote osteosarcoma cell survival during metastatic lung colonization 2023 ·Cellular Oncology ·(unknown), (unknown), (unknown), Matthew V. Cannon, (unknown), Amy C. Gross, Maren Cam, (unknown), Rebekka Duhen, Alexander E. Davies, Ryan D. Roberts	6
4	Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help 2023 ·Scientific Reports ·Terry R. Medler, Gwen Kramer, Shelly Bambina, Andrew J. Gunderson, Alejandro Alice, Tiffany C. Blair, (unknown), Thomas Duhen, Rebekka Duhen, Kristina H. Young, Marka R. Crittenden, Michael J. Gough	8
5	CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden 2023 ·Journal for ImmunoTherapy of Cancer ·Jitske van den Bulk, Manon van der Ploeg, Marieke E. Ijsselsteijn, Dina Ruano, Ruud van der Breggen, Rebekka Duhen, Koen Peeters, Arantza Fariña Sarasqueta, Els M.E. Verdegaal, Sjoerd H. van der Burg, Thomas Duhen, Noel F.C.C. de Miranda	21
6	OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines 2022 ·Frontiers in Immunology ·Rebekka Duhen, (unknown), Shawn M. Jensen, Srinivas Abbina, Suraj Abraham, Nikita Jain, A.M. Thomas, Andrew J. Geall, Hong‐Ming Hu, Bernard A. Fox, Andrew D. Weinberg	4
7	PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors 2022 ·Journal of Clinical Investigation ·Rebekka Duhen, (unknown), (unknown), Alexandra K. Frye, (unknown), Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen	45
8	959 PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Rebekka Duhen, (unknown), (unknown), Alexandra K. Frye, (unknown), Venkatesh Rajamanickam, David A. Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen	3
9	Tumor resident memory CD8 T cell formation and concomitant tumor immunity is CD40L dependent and CD4 independent. 2022 ·The Journal of Immunology ·Michael J. Gough, Gwen Kramer, Shelly Bambina, Alejandro Alice, Tiffany C. Blair, Thomas Duhen, Rebekka Duhen, Marka R. Crittenden	1
10	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells 2021 ·Nature Communications ·Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu‐Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg	114
11	Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors breakdown → 2018 ·Nature Communications ·Thomas Duhen, Rebekka Duhen, Ryan Montler, (unknown), Tarsem Moudgil, Noel F.C.C. de Miranda, Cheri P. Goodall, Tiffany C. Blair, Bernard A. Fox, Jason McDermott, Shu‐Ching Chang, Gary L. Grunkemeier, Rom S. Leidner, R. Bryan Bell, Andrew D. Weinberg	564
12	Neoadjuvant OX40 therapy in patients with head and neck cancer induces profound changes in tumor-infiltrating lymphocytes 2018 ·The Journal of Immunology ·Rebekka Duhen, Carmen Ballesteros‐Merino, R. Bryan Bell, Rom S. Leidner, Yoshinobu Koguchi, Carlo Bifulco, Bernard A. Fox, Andrew D. Weinberg	1
13	Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma. 2018 ·Journal of Clinical Oncology ·R. Bryan Bell, Rebekka Duhen, Rom S. Leidner, Brendan D. Curti, Carmen Ballesteros‐Merino, Brian Piening, Brady Bernard, Joanna Pucilowska, Carlo Bifulco, Bernard A. Fox, Thomas Duhen, William L. Redmond, Yoshinobu Koguchi, Allen Cheng, Ashish Patel, George Morris, Raina Tamakawa, (unknown), Walter J. Urba, Andrew D. Weinberg	23
14	S1P1 deletion differentially affects TH17 and Regulatory T cells 2017 ·Scientific Reports ·Ahmet Eken, Rebekka Duhen, Akhilesh K. Singh, (unknown), Jane H. Buckner, Mariko Kita, Estelle Bettelli, Mohamed Oukka	49
15	Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4 2015 ·Scientific Reports ·Simon Glatigny, Rebekka Duhen, (unknown), (unknown), Estelle Bettelli	40
16	IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis 2015 ·The Journal of Immunology ·(unknown), Simon Glatigny, Rebekka Duhen, Gérard Eberl, Mohamed Oukka, Estelle Bettelli	40
17	Integrin alpha 4 differentially affect the migration of effector and regulatory T cells (P4113) 2013 ·The Journal of Immunology ·Estelle Bettelli, Simon Glatigny, Rebekka Duhen, (unknown), (unknown), Mohamed Oukka	1
18	Cutting Edge: The Pathogenicity of IFN-γ–Producing Th17 Cells Is Independent of T-bet 2013 ·The Journal of Immunology ·Rebekka Duhen, Simon Glatigny, (unknown), Tiffany C. Blair, Mohamed Oukka, Estelle Bettelli	137
19	Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells 2012 ·Blood ·Thomas Duhen, Rebekka Duhen, Antonio Lanzavecchia, Federica Sallusto, Daniel Campbell	313
20	Cutting Edge: Loss of α4 Integrin Expression Differentially Affects the Homing of Th1 and Th17 Cells 2011 ·The Journal of Immunology ·Simon Glatigny, Rebekka Duhen, Mohamed Oukka, Estelle Bettelli	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact